Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Baxter
Express Scripts
Citi
UBS
Cantor Fitzgerald

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,748,382

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,748,382 protect, and when does it expire?

Patent 8,748,382 protects TYMLOS and is included in one NDA.

This patent has thirty-three patent family members in twenty-four countries.

Summary for Patent: 8,748,382
Title:Method of drug delivery for bone anabolic protein
Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
Inventor(s): Dey; Michael J. (Sandbach, GB), Mondoly; Nathalie (Le Chesnay, FR), Rigaud; Benedicte (Oulins, FR), Henderson; Bart (Belmont, MA), Lyttle; C. Richard (Bala Cynwyd, PA)
Assignee: Radius Health, Inc. (Cambridge, MA) Ipsen Pharma S.A.S. (Boulogne-Billancourt, FR)
Application Number:13/438,086
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,748,382

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Radius Health Inc TYMLOS abaloparatide SOLUTION;SUBCUTANEOUS 208743-001 Apr 28, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE. ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,748,382

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007322334 ➤ Sign Up
Brazil PI0719821 ➤ Sign Up
Brazil PI0722428 ➤ Sign Up
Canada 2664734 ➤ Sign Up
China 101578093 ➤ Sign Up
China 102274492 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Healthtrust
McKesson
McKinsey
Citi
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.